Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Interstitial Lung Disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    161 result(s) found for: Interstitial Lung Disease. Displaying page 7 of 9.
    « Previous 1  2  3  4  5  6  7  8  9  Next»
    EudraCT Number: 2022-003268-25 Sponsor Protocol Number: AT-03A-017 Start Date*: 2023-05-12
    Sponsor Name:Atea Pharmaceuticals, Inc.
    Full Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients with COVID-19
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) ES (Ongoing) LV (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-001995-13 Sponsor Protocol Number: BREATH-19 Start Date*: 2020-05-15
    Sponsor Name:Fundación SEIMC-GESIDA
    Full Title: A multicentre, open-label clinical trial to evaluate the effectiveness and safety of intravenous tocilizumab for treating patients with COVID-19 pneumonia: the BREATH-19 Study
    Medical condition: COVID-19 pneumonia
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-004323-16 Sponsor Protocol Number: RCT-MP-COVID-19 Start Date*: 2020-11-25
    Sponsor Name:AZIENDA OSPEDALIERA ARCISPEDALE SANTA MARIA NUOVA/IRCCS DI REGGIO EMILIA
    Full Title: A randomized, multicentre, double-blind study to evaluate the efficacy of high-dose administartion of methylprednisolone in addition to standard treatment, in SARS-CoV2 (COVID-19) pneumonia patients.
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10053983 Corona virus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004738-27 Sponsor Protocol Number: A011-09 Start Date*: 2018-08-15
    Sponsor Name:Acceleron Pharma Inc.
    Full Title: A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study to Compare the Efficacy and Safety of Sotatercept (ACE-011) Versus Placebo When Added to Standard of Care for the Treatment of Pulmonar...
    Medical condition: Pulmonary Arterial Hypertension (PAH)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10077739 Pulmonary arterial hypertension WHO functional class I LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-002692-33 Sponsor Protocol Number: H6D-MC-LVGY Start Date*: 2006-04-10
    Sponsor Name:Lilly ICOS LLC
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Phosphodiesterase Type 5 (PDE5) Inhibitor Tadalafil in the Treatment of Patients with Pulmonary Arterial Hypertension
    Medical condition: Pulmonary arterial hypertension (PAH) is a chronic and progressive disease characterised by elevation of pulmonary artery pressure and pulmonary vascular resistance, leading to right heart failure ...
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IE (Completed) DE (Completed) BE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2022-002741-18 Sponsor Protocol Number: GS-US-611-6273 Start Date*: 2022-12-19
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5245 for the Treatment of COVID-19 in Participants With High-Risk for Disease Progression
    Medical condition: Coronavirus disease 2019 (COVID-19) in patients who have a high risk of developing serious or severe illness
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) HU (Completed) ES (Ongoing) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-006504-32 Sponsor Protocol Number: ACTIV-2d/A5407 Start Date*: 2022-12-15
    Sponsor Name:Shionogi B.V.
    Full Title: A Phase 3, multicenter, randomized, double-blind, 24-week study of the clinical and antiviral effect of S-217622 compared with placebo in non-hospitalized participants with COVID-19
    Medical condition: SARS-CoV-2 infection
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10084272 SARS-CoV-2 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-000301-37 Sponsor Protocol Number: EFC13738 Start Date*: 2018-10-09
    Sponsor Name:Genzyme Corporation
    Full Title: Open label, Two Cohort (with and without Imiglucerase), Multicenter Study to Evaluate Pharmacokinetics, Safety, and Efficacy of Eliglustat in Pediatric Patients with Gaucher Disease Type 1 and Type 3
    Medical condition: Congenital, hereditary and neonatal diseases
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10075697 Gaucher's disease type I PT
    20.0 10010331 - Congenital, familial and genetic disorders 10075699 Gaucher's disease type III PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed) IT (Trial now transitioned) NL (Ongoing) ES (Ongoing) Outside EU/EEA GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-000342-60 Sponsor Protocol Number: 190280 Start Date*: 2016-06-21
    Sponsor Name:Norfolk and Norwich University Hospital
    Full Title: Fatigue in Sarcoidosis - A feasibility study investigating the treatment of fatigue in stable sarcoidosis patients using methylphenidate
    Medical condition: Sarcoidosis-associated fatigue (Patients with stable sarcoidosis and chronic fatigue)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021428 - Immune system disorders 10039486 Sarcoidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-001719-65 Sponsor Protocol Number: CALC-SSc Start Date*: 2018-12-10
    Sponsor Name:University Medial Center Groningen
    Full Title: CALCification as an early marker of vasculopathy and organ involvement in Systemic Sclerosis CALC-SSc study
    Medical condition: Systemic sclerosis (SSc) is a rare progressive autoimmune disease hallmarked by severe vasculopathy. Patients are prone to enhanced calcification of skin and the vasculature. Active calcifications ...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-002479-33 Sponsor Protocol Number: R2377 Start Date*: 2020-03-02
    Sponsor Name:Hull University Teaching Hospitals NHS Trust
    Full Title: A parallel group, double-blind, randomised, placebo-controlled trial comparing the effectiveness and cost effectiveness of low dose oral modified release morphine versus placebo on patient-reported...
    Medical condition: Chronic breathlessness due to cardiac, respiratory disease or cancer.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10007554 Cardiac failure PT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009026 Chronic obstructive airways disease LLT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10022611 Interstitial lung disease PT
    21.0 100000004864 10048683 Advanced cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2021-002390-25 Sponsor Protocol Number: E21-04 Start Date*: 2022-01-20
    Sponsor Name:Fab'entech
    Full Title: A two-stage randomized, placebo-controlled, double-blind, phase 2a study to characterize the safety and pharmacokinetics of FBR-002 in patients hospitalized with COVID-19 need of supplemental oxyge...
    Medical condition: COVID-19 in hospitalized patients in need of supplemental oxygen and at risk of severe outcome
    Disease: Version SOC Term Classification Code Term Level
    23.1 10042613 - Surgical and medical procedures 10084460 COVID-19 treatment PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004326-19 Sponsor Protocol Number: 69HCL19_0029 Start Date*: 2020-01-27
    Sponsor Name:Hospices Civils de Lyon
    Full Title: Pragmatic management of progressive disease in idiopathic pulmonary fibrosis: a randomized trial
    Medical condition: Idiopathic pulmonary fibrosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004998-34 Sponsor Protocol Number: B-2660-203 Start Date*: 2020-07-16
    Sponsor Name:Blade Therapeutics, Inc.
    Full Title: A Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate Pharmacodynamics, Pharmacokinetics, and Safety of BLD-2660 Administered Orally in Subjects with Idiopathic Pulmonary Fibrosis
    Medical condition: Idiopathic Pulmonary Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-002956-18 Sponsor Protocol Number: ZWI-ZW25-202 Start Date*: 2020-03-25
    Sponsor Name:Zymeworks Inc.
    Full Title: Phase 2a Study of ZW25 in Combination with Palbociclib Plus Fulvestrant
    Medical condition: Breast cancer patients including those with locally advanced (unresectable) or metastatic HER2-positive, HR-positive breast cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-006278-22 Sponsor Protocol Number: ORV-PF-01 Start Date*: 2022-08-29
    Sponsor Name:NeRRe Therapeutics Ltd
    Full Title: A DOUBLE-BLIND, RANDOMISED, PLACEBO CONTROLLED, TWO PERIOD CROSS-OVER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORVEPITANT IN CHRONIC COUGH IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS
    Medical condition: Chronic cough in patients with idiopathic pulmonary fibrosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10066656 Chronic cough LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004025-40 Sponsor Protocol Number: PA101-CC-02 Start Date*: 2015-02-06
    Sponsor Name:Patara Pharma
    Full Title: Treatment of Chronic Idiopathic Cough (CIC) and Chronic Cough in patients with Idiopathic Pulmonary Fibrosis (IPF) with PA101.
    Medical condition: Chronic Idiopathic Cough and Chronic Cough in Idiopathic Pulmonary Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004855 10066656 Chronic cough LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003279-23 Sponsor Protocol Number: MOMEL27 Start Date*: 2020-01-13
    Sponsor Name:Radboudumc
    Full Title: Phase 2 Study testing the COmbination of Vemurafenib With Cobimetinib in BRAF V600 mutated Melanoma Patients to Normalize LDH and Optimize immunotherapY with Nivolumab and Ipilimumab (COWBOY)
    Medical condition: Stage IV or unresectable stage III, BRAFV600E/K mutation positive melanoma, naïve for BRAF/MEK, PD-1/PD-L1 or CTLA-4 targeting therapy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-002724-12 Sponsor Protocol Number: E22-04 Start Date*: 2022-11-24
    Sponsor Name:Fab'entech
    Full Title: A phase IIb randomized, placebo-controlled, double-blind study, to evaluate the efficacy and safety of FBR-002 in participants hospitalized with COVID-19 in need of supplemental oxygen and at risk ...
    Medical condition: COVID-19 in hospitalized patients in need of supplemental oxygen and at risk of severe outcome
    Disease: Version SOC Term Classification Code Term Level
    23.1 10042613 - Surgical and medical procedures 10084460 COVID-19 treatment PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Prematurely Ended) BG (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-023437-30 Sponsor Protocol Number: A7281006 Start Date*: 2011-09-29
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-00547659 IN SUBJECTS WITH CROHN’S DISEASE(OPERA)
    Medical condition: Crohn's Disease
    Disease: Version SOC Term Classification Code Term Level
    16.1 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) BE (Completed) SE (Completed) AT (Completed) DE (Completed) PT (Prematurely Ended) NO (Completed) NL (Completed) ES (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 23 09:14:52 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA